P138	Endostatin altered endothelial cells in different ways.
A.Schmidt, W.Bloch
German Sport University Cologne, Dept. of Molecular and Cellular Sport Medicine, Cologne, DE.

Endostatin was described as an anti-angiogenic factor. Therefore endostatin looked to be a new way in anti-angiogenic treatment of cancer. Unfortunately, up to now no objective response were seen in clinical trials using endostatin. We compared two different endothelial cell models. Human umbilical vein endothelial cells (HUVEC) and endothelial cells derived from differentiated embryonic stem cells (eESC) were tested in view of endostatin induced proliferation, apoptosis, migration and endostatin binding. Both endothelial cell types had shown an opposite response to endostatin. For example the quantity of HUVEC cells was slightly reduced to 84±8% by treating with 50 ng/ml endostatin whereas the eESCs showed a significant increase up to 142±12% under same conditions (p=0.01). The observation that endostatin is able to alter ambivalently the proliferation, cell amount, migration of endothelial cells leads to the assumption that endostatin is not only an anti-angiogenic factor rather an angiogenic modulator.

Copyright © 2005 S. Karger AG, Basel. Any further use of this abstract requires written permission from the publisher.